CCA
BMY.RT

Canyon Capital Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Canyon Capital Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,246,794
Closed -$4.46M – 38
2020
Q2 		$4.46M Hold
1,246,794
– – 0.15% 25
2020
Q1 		$4.74M Hold
1,246,794
– – 0.17% 32
2019
Q4 		$3.75M Buy
+1,246,794
New +$3.24M 0.09% 32

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Canyon Capital Advisors's BMY.RT Position: Q3 2020 in Review

Canyon Capital Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 1,246,794 shares — an estimated $4.46M sold.

Canyon Capital Advisors first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $4.74M in Q1 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Canyon Capital Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Canyon Capital Advisors sold 1,246,794 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $4.46M.
  • Canyon Capital Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Canyon Capital Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4.74M in Q1 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Canyon Capital Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.